According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM) is €0.12 B. In 2023 the company made a revenue of €54.53 M an increase over the revenue in the year 2022 that were of €25.3 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.